Leerink Partners recently hosted a Rare Disease Roundtable that included fireside chats with 24 biopharmaceutical companies. Following the event, analyst Joseph Schwartz released a report that included a list of 20 Outperform-rated names that attended the roundtable.

Here’s a list of some of the potential catalysts Schwartz sees for these companies.

Highlighted Stocks And Catalysts

• Aegerion Pharmaceuticals, Inc. AEGR 2.16%: The company is guiding conservatively for Juxtapid sales.
• Agios Pharmaceuticals Inc AGIO 2.94%: The company is seeing clinical benefit in solid tumor indications.
• Alnylam Pharmaceuticals, Inc. ALNY 6.17%: The company reports solid enrollment in APOLLO Ph. III trial and positive OLE Phase II data.

• Ascendis Pharma A/S ASND 2.35%: The company is ramping…

Click here to continue reading

Want to learn more about how to profit off the stock market? Or maybe you just want to be able to look sophisticated in front of your coworkers when they ask you what you are reading on your Kindle, and you’d prefer to tell them “Oh, I’m just reading a book about stock market analysis,” rather than the usual “Oh, I’m just looking at pics of my ex-girlfriend on Facebook.” For these reasons and more, check out my book, Beating Wall Street with Common Sense. I don’t have a degree in finance; I have a degree in neuroscience. You don’t have to predict what stocks will do if you can predict what traders will do and be one step ahead of them. I made a 400% return in the stock market over five years using only basic principles of psychology and common sense. Beating Wall Street with Common Sense is now available on Amazon, and tradingcommonsense.com is always available on your local internet!